Program
Friday, April 21st 2023
Registration and Get Together
Introduction and Opening Remarks
Marc S. Raab, Heidelberg
Hartmut Goldschmidt, Heidelberg
Carsten Müller-Tidow, Heidelberg
Ingo Autenrieth, Heidelberg
Niels Weinhold, Heidelberg
Session I: Evolution & Treatment of SMM
Chair:
Patrick Hayden, Dublin
Elias Mai, Heidelberg
The evolutionary pathways leading to multiple myeloma
Brian Walker, Indianapolis
Treatment of high-risk smoldering: pros
Maria Victoria Mateos, Salamanca
Treatment of high-risk smoldering: cons
Sagar Lonial, Atlanta
Discussion
Session II: Minimally Invasive Response Assessment
Chair: Stefan Delorme, Heidelberg
Using PET for response assessment (Update)
Carolina Schinke, Arkansas
Mass spectrometry
Elias Mai, Heidelberg
Using MRI for response assessment (Update)
Jens Hillengass, Buffalo
Discussion
Coffee Break
Session III: Current Concepts for Newly Diagnosed Myeloma
Chair:
Hans Salwender, Hamburg
Sandra Sauer, Heidelberg
First-line transplant eligible (Update)
Hartmut Goldschmidt, Heidelberg
CONCEPT trial (Update)
Katja Weisel, Hamburg
MASTER trial (Update)
Ola Landgren, Miami
First-line transplant ineligible
Thierry Facon, Lille
Discussion
Coffee Break
Key Note Lecture
Novel Agents Beyond Immunotherapy
Shaji Kumar, Rochester
Session IV: Curing Myeloma
Chair:
Monika Engelhardt, Freiburg
Stefanie Huhn, Heidelberg
Risk-stratified treatment approaches
Martin Kaiser, London
The evolutionary pathways of myeloma cells in deep-responding patients
Leo Rasche, Würzburg
Treatment decisions based on MRD data: pros
Bruno Paiva, Pamplona
Treatment decisions based on MRD data: cons
Martin Kaiser, London
Discussion
Short Summary and End of Day 1
Marc-Steffen Raab, Heidelberg
Saturday, April 22nd 2023
Get Together
Key Note Lecture
What is the Next Bbig Thing in Myeloma Therapy?
Kenneth C. Anderson, Boston
Session I: Myeloma Genomics
Chair:
Leo Rasche, Würzburg
Niels Weinhold, Heidelberg
Complex structural aberrations and impact on outcome
Gareth Morgan, New York
Mutational signatures
Francesco Maura, Miami
Impact of genomic complexity on the transcriptome of multiple myeloma
Niccolo Bolli, Milano
Discussion
Coffee Break
Session II: Immunotherapy I
Chair: Peter Dreger, Heidelberg
CD38 Antibody treatment
Philippe Moreau, Nantes
Current CAR-T cells – Clinical overview
Paula Rodriguez Otero, Pamplona
CAR real world data
Christoph Scheid, Köln
Role of BM microenvironment in MM progression and response to CAR-T therapies in myeloma
Paola Neri, Calgary
Discussion
Lunch
Session III: Immunotherapy II
Chair: Markus Munder, Mainz
Leif Bergsagel, Scottsdale
Novel CAR-T cell constructs
Hermann Einsele, Würzburg
Antibody-drug conjugates
Suzanne Trudel, Toronto
Immune microenvironment stroma cells
Tom Cupedo, Rotterdam
T-cell engagers, a clinical update
Nizar Bahlis, Calgary
Discussion
Coffee Break
Session IV: Novel Resistance Mechanisms
Chair:
Christoph Driessen, St. Gallen
Florian Bassermann, München
PI and IMID Resistance
Martin Kortüm, Würzburg
Combination of SOC and bispecific antibodies: lessons from an IMID-responsive immunocompetent mouse model
Marta Chesi, Scottsdale
Proteomic studies to uncover non-genetic resistance mechanisms in myeloma
Jan Krönke, Berlin
Immunotherapeutic vulnerabilities
Jens Lohr, Boston
Immunological mechanisms and determinants of response to T cell-redirecting therapies
Mirco Friedrich, Cambridge
Discussion
Summary and Closing of the Workshop
Marc-Steffen Raab, Heidelberg